title: Five Patients With Burning Mouth Syndrome in Whom an Antidepressant (Serotonin-Noradrenaline Reuptake Inhibitor) Was Not Effective, but Pregabalin Markedly Relieved Pain.
abstract: Burning mouth syndrome (BMS) causes idiopathic pain or a burning sensation in clinically normal oral mucosa. Burning mouth syndrome is a chronic disease with an unknown etiology. Burning mouth syndrome is also idiopathic, and a consensus regarding diagnosis/treatment has not been reached yet. Recent studies have supported the suggestion that BMS is a neuropathic pain disorder in which both the peripheral and central nervous systems are involved. Tricyclic antidepressants (nortriptyline and amitriptyline), serotonin-noradrenaline reuptake inhibitors (SNRIs) (duloxetine and milnacipran), and antiepileptic drugs, potential-dependent calcium channel α2δ subunit ligands (gabapentine and pregabalin), are currently recommended as the first-choice drugs for neuropathic pain. In this study, we report 5 patients with BMS in whom there was no response to SNRI (milnacipran or duloxetine), or administration was discontinued because of adverse reactions, but in whom pregabalin therapy markedly reduced or led to the disappearance of pain in a short period. Pregabalin, whose mechanism of action differs from that of SNRIs, may become a treatment option for BMS patients who are not responsive to or are resistant to SNRIs.
authors.affiliation: From the *Department of Oral and Maxillofacial Surgery, School of Dentistry, Aichi-Gakuin University, Nagoya; †Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya; and ‡Health Care Promotion Division, Denso Corporation, Aichi, Japan.
authors.forename: Mikiko
authors.initials: M
authors.lastname: Ito
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Tokura
authors.forename: Keizo
authors.initials: K
authors.lastname: Yoshida
authors.forename: Wataru
authors.initials: W
authors.lastname: Nagashima
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kimura
authors.forename: Eri
authors.initials: E
authors.lastname: Umemura
authors.forename: Masako
authors.initials: M
authors.lastname: Tachibana
authors.forename: Tomoya
authors.initials: T
authors.lastname: Miyauchi
authors.forename: Yuka
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Munetaka
authors.initials: M
authors.lastname: Arao
authors.forename: Norio
authors.initials: N
authors.lastname: Ozaki
authors.forename: Kenichi
authors.initials: K
authors.lastname: Kurita
mesh_terms: D000368:Aged; D000700:Analgesics / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D002054:Burning Mouth Syndrome / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069583:Pregabalin / Q000627:therapeutic use*
chemical_list: D000700:Analgesics; D000928:Antidepressive Agents; D000069583:Pregabalin